STAAR Surgical Highlights Premium Cash Value In Alcon Merger Presentation; Soleus Capital Signals Support Ahead Of Shareholder Vote

Author: Benzinga Newsdesk | September 26, 2025 07:29am

Proposed Merger Represents a Compelling 59% Premium to the 90-Day VWAP Prior to Announcement

STAAR's Business Risks and Challenges are Increasing and Competition is Intensifying

China Net Sales, which Represent Approximately Half of STAAR's Consolidated Net Sales, Have Declined Since 2023, and Procedure Volumes Remain Weak

Broadwood Partners' Claims Against the Merger are Flawed and Misleading and Reflect a Misunderstanding of STAAR's Standalone Challenges, Value, and Potential Buyer Interest in STAAR

STAAR's Stock Traded at $18.49 per Share Prior to Announcement – If the Merger is not Approved, STAAR Expects its Valuation Would Face Considerable Downward Pressure, Especially in Light of Intensifying Competition and Increased Business Risks

All STAAR Stockholders Encouraged to Vote "FOR" Alcon Merger on the WHITE Proxy Card

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today published a presentation reviewing the compelling, certain, premium cash value offered by the Company's pending merger with Alcon (NYSE: ALC) and the meaningful downside risks for STAAR stockholders if the Alcon merger is not approved. The presentation is available at investors.staar.com and has been filed with the U.S. Securities and Exchange Commission.

STAAR also announced that the Company's second largest active stockholder, Soleus Capital Master Fund, L.P. ("Soleus Capital"), has informed the Board that it is supportive of the merger and intends to vote in favor absent a material change in circumstances. As of the record date, Soleus Capital owned approximately 6% of STAAR's outstanding shares.

Posted In: ALC STAA